Clinical TrialMay 29, 2026, 08:02 AM
SAB Biotherapeutics to Present SAB-142 Data at ADA & FOCIS
AI Summary
SAB Biotherapeutics announced it will present data on its lead program, SAB-142, at two major congresses in June 2026. An oral presentation at the American Diabetes Association's Scientific Sessions will cover clinical safety, pharmacokinetics, immunogenicity, and pharmacodynamics of repeat dosing. A poster presentation at the Federation of Clinical Immunology Societies Annual Meeting will detail the positive clinical translation of a juvenile NHP study for SAB-142. The company's Chief Medical Officer highlighted these forums as key opportunities to showcase SAB-142's profile and advance the registrational Phase 2b SAFEGUARD study, with topline data expected in the second half of 2027.
Key Highlights
- SAB Biotherapeutics to present data on its lead program, SAB-142, at two congresses in June 2026.
- An oral presentation at the ADA Scientific Sessions is scheduled for June 5, 2026.
- A poster presentation at the FOCIS Annual Meeting is scheduled for June 10, 2026.
- Presentations will cover clinical safety, pharmacokinetics, immunogenicity, and pharmacodynamics of SAB-142.
- Data will also highlight positive clinical translation from a juvenile NHP study for SAB-142.
- SAB-142 is a potentially disease-modifying immunotherapy for newly diagnosed Stage 3 T1D.
- The company anticipates topline data readout for the registrational Phase 2b SAFEGUARD study in 2H 2027.
Price Impact
More from SABS